You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)升見十個月高位 里昂上調目標價至40.2元評級「買入」
阿思達克 01-27 11:48
和黃醫藥(00013.HK)三連升,今日(27日)平開報31.5元後,最高曾見32.2元創約十個月高。現報31.8元,升近1%,成交144.2萬股,涉資4,565.3萬元。 公司日前公布,子公司和黃醫藥(上海)與日本武田藥品(Takeda)達成(口夫)(口奎)替尼(fruquintinib)開發及商業化許可協議,在除內地、香港和澳門以外的全球範圍內進一步推進(口夫)(口奎)替尼的開發、商業化和生產。和黃醫藥(上海)將獲得總額可高達11.3億美元付款,其中,包括4億美元首付款,以及潛在的監管註冊、開發和商業銷售里程碑付款,並外加基於淨銷售額的特許權使用費。該藥可通過口服給藥,並有潛力用於轉移性結直腸癌的各種亞型中且不受生物標誌物狀態影響。 里昂發表報告,認為是次交易為fruquintinib海外潛在發展奠定基礎,亦印證和黃醫藥臨床能力受國際藥廠認可,並強化和黃醫藥現金狀況。該行更新對其盈虧預測,H股目標價由30元升至40.2元,評級「買入」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account